Cyramza 500 MG/50 ML vial 50ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFBT4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,136
Award facts
- Contract value 100% obligated
- $33,136.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,136.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Cyramza 500 mg/50 ml vials. This firm fixed-price delivery order, issued on December 29, 2025, with an ultimate completion date of January 21, 2026, was made without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated SPE2DR, which was awarded on November 13, 2025, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
The PPV-G GEN V program represents a broader $30.3 billion acquisition strategy through which the DLA establishes multiple regional prime vendor contracts to supply comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. Under this contract structure, DMS Pharmaceutical Group holds a $499,999,999 ceiling with a base period through December 31, 2036, enabling the company to fulfill recurring medical supply requirements for military healthcare operations globally. The company's extensive product portfolio includes oncology treatments, biologics, vaccines, specialty pharmaceuticals, and routine medications, positioning it as a critical supplier within the federal military medical pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FFBT4?
SPE2DR26FFBT4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FFBT4 worth?
The government has obligated $33,136 on SPE2DR26FFBT4.
Is contract SPE2DR26FFBT4 an order under another contract?
Yes. SPE2DR26FFBT4 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBT4 competed?
The extent of competition for SPE2DR26FFBT4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award